The first edition of the Global DDI Solutions Lung Cancer webinar took place on 22 April 2024. This webinar is organized by Global DDI Solutions in collaboration with Academic Medical Education.

In 2022, more than 2 million cases of lung cancer were recorded, making it the second most prolific cancer in the world. With new therapies such as small molecule inhibitors (SMIs) and immune/chemotherapy, several pharmacological, including drug-drug interactions (DDIs), issues have arisen that need the full attention of clinicians, pharmacists, pulmonologists, medical oncologists, nurse specialists, and clinical researchers and pharmacologist.

Meeting Objectives
• Raise awareness for DDI with SMIs and DOACs and provide guidelines for DDI management;
• Provide guidelines for therapeutic drug monitoring for SMIs in the clinic;
• Give an overview of the benefits and limitations of flat fixed versus weight-based immunotherapy dosing.

How do you avoid adverse drug interactions in this rapidly evolving field of pharmacological therapies?  

Presented by Global DDI Solutions in collaboration with Academic Medical Education, the DDI of the Month podcast brings you the latest updates on drug-drug interactions.

Each month, a new paper will be selected and the author invited to discuss their findings and explore how this can optimize DDI management and patient care going forward. The podcast is intended for everyone interested in DDI management or specific drugs, e.g. healthcare professionals, pharmacists, and researchers.

Episode 1 is live! Available here as well as on Spotify and Apple Podcast!

In the first exciting episode of this new podcast series, Dr. Iversen and Dr. Burger will dive into DDIs with flucloxacillin, and explore the results of Dr. Iversen’s research trial. Flucloxacillin is widely used to treat infections and is known to be an agonist of the nuclear receptor PXR. Combined with comedications, it may give an increased risk of drug-drug interactions and no guideline is available yet.

The Course on Clinical Pharmacology of SARS-CoV-2 Antivirals held on Tuesday, 17 May 2022, was a great success! We are delighted to announce that the videos and presentation slide sets are now available (free to access) on our AME website!

The COVID-19 pandemic has had a huge toll in terms of morbidity and mortality worldwide. Immunocompromised patients as well as patients over the age of 60 with comorbidities and underlying conditions are the most at risk of developing the severe disease as a result of COVID-19. These patients are also exposed to multiple medications to treat their chronic conditions. Therefore, if they require treatment for COVID-19 with new SARS-CoV-2 antivirals, this can lead to several potentially complex and serious drug-drug interactions that can result in severe side effects or reduce the drugs’ therapeutic effect.

The Course on Clinical Pharmacology of SARS-CoV-2 Antivirals gathered healthcare professionals who prescribe oral antivirals for COVID-19 to discuss their therapeutic effects, the management of drug-drug interactions, and the identification of risk factors, as well as leaving ample time for case-based discussions.

The first edition of the Course on Clinical Pharmacology of SARS-CoV-2 Antivirals was organized by Global DDI Solutions, in collaboration with Virology Education, the University of Liverpool, and Radboud University Medical Center Nijmegen.